Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Hugel Inc. (145020:KRX), powered by AI.
Hugel Inc. is currently trading at ₩258,000. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Hugel Inc. on Alpha Lenz.
Hugel Inc.'s P/E ratio is 22.5.
“Hugel Inc. trades at a P/E of 22.5 (fair value) with strong ROE of 16.1%. 3Y revenue CAGR of 14.7% highlights clear growth momentum.”
Ask for details →Hugel Inc. is a biopharmaceutical company known for its specialization in the development and commercialization of botulinum toxin-related products and other aesthetic medicine solutions. Leveraging its expertise in biotechnology, Hugel is committed to innovating in the field of cosmetic and functional therapies. The company's primary focus is on treatments for aesthetic and medical issues such as wrinkles, muscular disorders, and excessive sweating. Hugel Inc. significantly influences the healthcare and cosmetics sectors by offering an array of injectables, fillers, and cosmeceutical products. Headquartered in South Korea, the company's operations extend globally, highlighting its strategic market presence in both Asian and international arenas. Hugel stands as a prominent player in the industry, dedicated to enhancing quality of life through advanced medical solutions and expanding its reach in the burgeoning market for aesthetic medicines.
“Hugel Inc. trades at a P/E of 22.5 (fair value) with strong ROE of 16.1%. 3Y revenue CAGR of 14.7% highlights clear growth momentum.”
Ask for details →Hugel Inc. (ticker: 145020) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 589 employees. Market cap is $3.2T.
The current price is ₩258,000 with a P/E ratio of 22.53x and P/B of 3.34x.
ROE is 16.06% and operating margin is 47.25%. Annual revenue is $425.1B.